X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (83) 83
anticoagulants - therapeutic use (66) 66
anticoagulants - adverse effects (54) 54
female (24) 24
male (23) 23
index medicus (22) 22
aged (20) 20
hemorrhage - chemically induced (20) 20
medicine, general & internal (19) 19
middle aged (19) 19
heparin - therapeutic use (18) 18
anticoagulants (16) 16
randomized controlled trials as topic (16) 16
anticoagulants - administration & dosage (15) 15
adult (14) 14
heparin - adverse effects (14) 14
administration, oral (13) 13
deep-vein thrombosis (13) 13
treatment outcome (13) 13
warfarin - adverse effects (13) 13
warfarin - therapeutic use (13) 13
molecular-weight heparin (12) 12
anticoagulants/adverse effects/therapeutic use (11) 11
heparin, low-molecular-weight - therapeutic use (11) 11
risk factors (11) 11
anticoagulants [adverse effects; therapeutic use] (10) 10
risk (10) 10
heparin, low-molecular-weight - adverse effects (9) 9
platelet aggregation inhibitors - therapeutic use (9) 9
therapeutic use (9) 9
venous thromboembolism (9) 9
warfarin (9) 9
atrial fibrillation - drug therapy (8) 8
hemorrhage/chemically induced (8) 8
rivaroxaban (8) 8
venous thrombosis - prevention & control (8) 8
adverse effects (7) 7
aged, 80 and over (7) 7
anticoagulants/administration & dosage/adverse effects/therapeutic use (7) 7
drug therapy (7) 7
stroke - prevention & control (7) 7
thromboembolism (7) 7
time factors (7) 7
abridged index medicus (6) 6
antithrombins - therapeutic use (6) 6
drug therapy, combination (6) 6
enoxaparin (6) 6
enoxaparin - adverse effects (6) 6
enoxaparin - therapeutic use (6) 6
fibrinolytic agents - therapeutic use (6) 6
hemorrhage (6) 6
heparin (6) 6
heparin, low-molecular-weight [adverse effects; therapeutic use] (6) 6
morpholines - therapeutic use (6) 6
pharmacology & pharmacy (6) 6
prevention (6) 6
pulmonary embolism - prevention & control (6) 6
thiophenes - therapeutic use (6) 6
thrombocytopenia - chemically induced (6) 6
tomography, x-ray computed (6) 6
venous thromboembolism - prevention & control (6) 6
administration (5) 5
antithrombotic therapy (5) 5
drug interactions (5) 5
evidence-based medicine (5) 5
factor xa inhibitors (5) 5
hemorrhage [chemically induced] (5) 5
heparin [adverse effects; therapeutic use] (5) 5
morpholines - adverse effects (5) 5
oral (5) 5
prevention & control (5) 5
pulmonary-embolism (5) 5
recurrence (5) 5
secondary prevention (5) 5
stroke - drug therapy (5) 5
therapy (5) 5
thiophenes - adverse effects (5) 5
thrombosis (5) 5
antineoplastic agents - adverse effects (4) 4
aspirin (4) 4
aspirin - therapeutic use (4) 4
atrial fibrillation - complications (4) 4
azetidines - therapeutic use (4) 4
cardiac & cardiovascular systems (4) 4
clinical trials as topic (4) 4
dosage and administration (4) 4
double-blind (4) 4
double-blind method (4) 4
drug administration schedule (4) 4
enoxaparin/adverse effects/therapeutic use (4) 4
fibrinolytic agents - adverse effects (4) 4
incidence (4) 4
injections, subcutaneous (4) 4
international normalized ratio (4) 4
medical and health sciences (4) 4
medicin och hälsovetenskap (4) 4
medicine general & introductory medical sciences (4) 4
metaanalysis (4) 4
oral anticoagulant-therapy (4) 4
placebo-controlled trial (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 06/2008, Volume 358, Issue 26, pp. 2765 - 2775
Rivaroxaban is an orally administered direct inhibitor of factor Xa. As compared with enoxaparin, rivaroxaban was more effective in preventing venous... 
ORAL XIMELAGATRAN | MEDICINE, GENERAL & INTERNAL | FACTOR-XA INHIBITOR | KNEE REPLACEMENT | BAY-59-7939 | DEEP-VENOUS THROMBOSIS | MOLECULAR-WEIGHT HEPARIN | MAJOR ORTHOPEDIC-SURGERY | DOUBLE-BLIND | PREVENTION | THROMBOEMBOLISM | Thiophenes - therapeutic use | Pulmonary Embolism - prevention & control | Venous Thromboembolism - mortality | Factor Xa Inhibitors | Thiophenes - adverse effects | Humans | Middle Aged | Male | Enoxaparin - therapeutic use | Pulmonary Embolism - epidemiology | Enoxaparin - adverse effects | Rivaroxaban | Venous Thromboembolism - prevention & control | Aged, 80 and over | Adult | Female | Venous Thrombosis - prevention & control | Morpholines - adverse effects | Morpholines - therapeutic use | Double-Blind Method | Anticoagulants - therapeutic use | Arthroplasty, Replacement, Hip | Anticoagulants - adverse effects | Venous Thrombosis - epidemiology | Adolescent | Aged | Enoxaparin | Dosage and administration | Blood coagulation factors | Comparative analysis | Health aspects | Hip joint | Clinical trials | Comparative studies | Joint surgery | Drug therapy | Clinical outcomes | Blood clots | Index Medicus | Abridged Index Medicus | Enoxaparin/adverse effects/therapeutic use | Venous Thrombosis/epidemiology/prevention & control | Thiophenes/adverse effects/therapeutic use | Arthroplasty | Replacement | Kirurgi | Hip | Morpholines/adverse effects/therapeutic use | 80 and over | Surgery | Anticoagulants/adverse effects/therapeutic use | Venous Thromboembolism/mortality/prevention & control | Factor Xa/antagonists & inhibitors | Pulmonary Embolism/epidemiology/prevention & control
Journal Article
Chest, ISSN 0012-3692, 2004, Volume 126, Issue 3, pp. 338S - 400S
This article discusses the prevention of venous thromboembolism (VTE) and is part of the Seventh American College of Chest Physicians Conference on... 
Aspirin | Warfarin | Deep-vein thrombosis | Fondaparinux | Prophylaxis | Heparin | Low-molecular-weight heparin | Thromboembolism | Postoperative Complications - etiology | Pulmonary Embolism - prevention & control | Humans | Postoperative Complications - prevention & control | Heparin, Low-Molecular-Weight - adverse effects | Heparin - therapeutic use | Heparin - adverse effects | Heparin, Low-Molecular-Weight - therapeutic use | Dose-Response Relationship, Drug | Vitamin K - antagonists & inhibitors | Aspirin - adverse effects | Venous Thrombosis - prevention & control | Aspirin - therapeutic use | Drug Therapy, Combination | Polysaccharides - therapeutic use | Drug Administration Schedule | Risk Assessment | Polysaccharides - adverse effects | Anticoagulants - therapeutic use | Anticoagulants - adverse effects | Evidence-Based Medicine | Venous Thrombosis - etiology | Randomized Controlled Trials as Topic | International Normalized Ratio | Pulmonary Embolism - etiology | Dose-Response Relationship; Drug | Polysaccharides/adverse effects/therapeutic use | Pulmonary Embolism/etiology/prevention & control | Randomized Controlled Trials | Anticoagulants/adverse effects/therapeutic use | Aspirin/adverse effects/therapeutic use | Drug Therapy; Combination | Heparin/adverse effects/therapeutic use | Heparin; Low-Molecular-Weight/adverse effects/therapeutic use | Venous Thrombosis/etiology/prevention & control | Postoperative Complications/etiology/prevention & control | Vitamin K/antagonists & inhibitors
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2012, Volume 366, Issue 14, pp. 1287 - 1297
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2012, Volume 366, Issue 1, pp. 9 - 19
Journal Article
The Cochrane database of systematic reviews, ISSN 1469-493X, 2014, Volume 8, Issue 8, p. CD008500
Background Venous thromboembolism (VTE) often complicates the clinical course of cancer. The risk is further increased by chemotherapy, but the safety and... 
Hemorrhage [chemically induced] | Pulmonary Embolism [etiology; prevention & control] Randomized Controlled Trials as Topic | LOW-DOSE WARFARIN | Humans | Anticoagulants [adverse effects; therapeutic use] | RANDOMIZED-TRIAL | Antithrombins [therapeutic use] | Heparin [adverse effects; therapeutic use] | Ambulatory Care | Heparin, Low-Molecular-Weight [adverse effects; therapeutic use] | Neoplasms [complications; drug therapy] | BLEEDING COMPLICATIONS | CELL LUNG-CANCER | MEDICINE, GENERAL & INTERNAL | PHASE-II TRIAL | Venous Thromboembolism [etiology; prevention & control] Warfarin [adverse effects; therapeutic use] | MOLECULAR-WEIGHT HEPARIN | METASTATIC BREAST-CANCER | Adult | MEDICAL PATIENTS | Antineoplastic Agents [adverse effects] | PLACEBO-CONTROLLED TRIAL | Child | DEEP-VEIN-THROMBOSIS | Pulmonary Embolism - prevention & control | Antithrombins - therapeutic use | Heparin, Low-Molecular-Weight - adverse effects | Warfarin - adverse effects | Anticoagulants - therapeutic use | Heparin - therapeutic use | Anticoagulants - adverse effects | Heparin - adverse effects | Heparin, Low-Molecular-Weight - therapeutic use | Neoplasms - drug therapy | Randomized Controlled Trials as Topic | Venous Thromboembolism - etiology | Warfarin - therapeutic use | Neoplasms - complications | Venous Thromboembolism - prevention & control | Antineoplastic Agents - adverse effects | Pulmonary Embolism - etiology | Hemorrhage - chemically induced
Journal Article
Thrombosis and Haemostasis, ISSN 0340-6245, 01/2009, Volume 101, Issue 1, pp. 77 - 85
Dabigatran etexilate has been investigated in three phase III trials for the prevention of venous thromboembolism (VTE). Health technology assessment agencies... 
anticoagulants | thrombosis | prophylaxis | Embolism | Meta-analysis | Anticoagulants | Thrombosis | Prophylaxis | ENOXAPARIN | meta-analysis | RANDOMIZED-TRIAL | REPLACEMENT | ORTHOPEDIC-SURGERY | MOLECULAR-WEIGHT HEPARIN | THROMBOSIS PROPHYLAXIS | US HOSPITALS | PERIPHERAL VASCULAR DISEASE | THROMBOPROPHYLAXIS | HEMATOLOGY | UNFRACTIONATED HEPARIN | REGISTRY | Venous Thromboembolism - mortality | Anticoagulants - administration & dosage | Arthroplasty, Replacement, Knee - adverse effects | Humans | Dabigatran | Enoxaparin - therapeutic use | Enoxaparin - adverse effects | Venous Thromboembolism - prevention & control | Clinical Trials, Phase III as Topic | Enoxaparin - administration & dosage | Pyridines - adverse effects | Benzimidazoles - administration & dosage | Benzimidazoles - adverse effects | Benzimidazoles - therapeutic use | Pyridines - therapeutic use | Pyridines - administration & dosage | Drug Administration Schedule | Risk Assessment | Administration, Oral | Anticoagulants - therapeutic use | Treatment Outcome | Anticoagulants - adverse effects | Arthroplasty, Replacement, Hip - adverse effects | Venous Thromboembolism - etiology | Hemorrhage - chemically induced | Administration | Phase III as Topic | Benzimidazoles/administration & dosage/adverse effects/therapeutic use | Pyridines/administration & dosage/adverse effects/therapeutic use | Arthroplasty | Replacement | Oral | Clinical Trials | Kirurgi | Knee/adverse effects | Hemorrhage/chemically induced | Venous Thromboembolism/etiology/mortality/prevention & control | Hip/adverse effects | Anticoagulants/administration & dosage/adverse effects/therapeutic use | Surgery | Enoxaparin/administration & dosage/adverse effects/therapeutic use
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 12/2016, Volume 2016, Issue 12, p. CD008500
Background Venous thromboembolism (VTE) often complicates the clinical course of cancer. The risk is further increased by chemotherapy, but the trade-off... 
Hemorrhage [chemically induced] | Pulmonary Embolism [etiology; prevention & control] Randomized Controlled Trials as Topic | LOW-DOSE WARFARIN | Humans | Anticoagulants [adverse effects; therapeutic use] | RANDOMIZED-TRIAL | Antithrombins [therapeutic use] | Heparin [adverse effects; therapeutic use] | FACTOR-BEARING MICROPARTICLES | Ambulatory Care | Heparin, Low-Molecular-Weight [adverse effects; therapeutic use] | Neoplasms [complications; drug therapy] | BLEEDING COMPLICATIONS | CELL LUNG-CANCER | MEDICINE, GENERAL & INTERNAL | PHASE-II TRIAL | Venous Thromboembolism [etiology; prevention & control] Warfarin [adverse effects; therapeutic use] | MOLECULAR-WEIGHT HEPARIN | METASTATIC BREAST-CANCER | Adult | Antineoplastic Agents [adverse effects] | PLACEBO-CONTROLLED TRIAL | Child | DEEP-VEIN-THROMBOSIS | Pulmonary Embolism - prevention & control | Antithrombins - therapeutic use | Heparin, Low-Molecular-Weight - adverse effects | Warfarin - adverse effects | Anticoagulants - therapeutic use | Heparin - therapeutic use | Anticoagulants - adverse effects | Heparin - adverse effects | Heparin, Low-Molecular-Weight - therapeutic use | Neoplasms - drug therapy | Randomized Controlled Trials as Topic | Venous Thromboembolism - etiology | Warfarin - therapeutic use | Neoplasms - complications | Venous Thromboembolism - prevention & control | Antineoplastic Agents - adverse effects | Pulmonary Embolism - etiology | Hemorrhage - chemically induced
Journal Article